Group 1 - The company reported total revenue of $14 million for the first quarter of fiscal 2026, which ended on July 31, 2025 [1] - Adjusted EBITDA for the same period was $60,000, indicating a stable financial performance [1] - Rob Brainin has been appointed as the new Chief Executive Officer to lead the company through its next phase of growth [1] Group 2 - The appointment of Rob Brainin is seen as a strategic move at a critical inflection point for the company [1] - The company is positioned for potential growth in the oncology research sector [1]